RAPT Therapeutics Inc (RAPT)

3.21 -0.10 (-3.02%)
Real-time Cboe USD Disclaimer

RAPT Therapeutics Inc Company Profile

Sector
Healthcare
Employees
131
Equity Type
ORD
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Contact Information
Address
South San Francisco,94080 United States
Phone
650 489 9000
Fax
-
Top Executives
Name
Age
Since
Title
Brian Russell Wong 49 2015 CEO, President & Director
Linda Kozick 64 2016 Independent Director
William J. Rieflin 61 2015 Independent Chairman of the Board
Michael F. Giordano 63 2018 Independent Director
Alexander Rudensky 0 0000 Chairman of Scientific Advisory Board
David V. Goeddel 69 2015 Member of Scientific Advisory Board
Drew Mark Pardoll 0 2017 Member of Scientific Advisory Board
Antoni Ribas 54 0000 Member of Scientific Advisory Board
Robert Zamboni 0 0000 Member of Scientific Advisory Board
Scott Joseph Antonia 0 2017 Member of Scientific Advisory Board
Emma Guttman-Yassky 0 2019 Member of Scientific Advisory Board
Philip D. Greenberg 0 2017 Member of Scientific Advisory Board
Wendye Robbins 60 2019 Independent Director
Mary Ann Gray 69 2019 Independent Director
Lori M. Lyons-Williams 46 2021 Independent Director
Lawrence Fong 0 2020 Member of Scientific Advisory Board
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles